Ocumension Therapeutics (HKG:1477) reported 132.3 million yuan in loss for the first half of 2025, narrowing from a loss of 151.3 million yuan a year earlier, according to a Thursday filing with the Hong Kong bourse.
Loss per share was 0.17 yuan, compared with 0.23 yuan in the prior year.
Revenue at the drug company increased 75% year-on-year to 294 million yuan, figures showed.
Meanwhile, in a separate announcement, the company said its OT-301 drug candidate met the main goal of a second late-stage study.
The drug was found to be non-inferior to the current standard of care latanoprost in the phase 3 Denali trial of subjects with an eye condition called pen-angle glaucoma or ocular hypertension.
As a result, the medicine now meets the requirements for new drug approval in China, the firm said.
Ocumension Therapeutics is developing OT-301, also known as NCX 470, with Nicox.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.